This is a retrospective, observational, post-marketing study to evaluate the clinical response, microbiological response, mortality, and safety of intravenous polymyxin B and colistin methanesulfonate in patients with carbapenem-resistant gram-negative bacterial infection. Subgroup analysis by sites of infection, infectious pathogens, and baseline renal function will also be performed.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Clinical response rate of polymyxin B and CMS treatment groups at TOC
Timeframe: TOC: End of Treatment + 7 days
Microbiological response rate of polymyxin B and CMS treatment groups at TOC
Timeframe: TOC: End of Treatment + 7 days
All-cause mortality of of polymyxin B and CMS treatment groups at Day 28
Timeframe: Day 28 from start of treatment
Clinical response rate of polymyxin B group by sites of infection and infectious pathogens at TOC
Timeframe: End of Treatment + 7 days
Microbiological response rate of polymyxin B group by sites of infection and infectious pathogens at TOC
Timeframe: End of Treatment + 7 days
Infection-related mortality of two treatment groups at Day 28
Timeframe: Day 28 from start of treatment